Integrin receptor antagonists and their methods of use
US9896480B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 9, 2012 |
| Grant date | Feb 20, 2018 |
| Priority date | — |
| Expiry date | Jul 17, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L2300/252
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to α5β1-Integrin, αvβ3-Integrin and αvβ5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.